CYTK - Cytokinetics, Incorporated Последние... | Finranks

26.03.2026

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

18.03.2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 13, 2026 it granted stock options to purchase an aggregate of 8,628 shares of common stock and 5,719 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in February and March 2026 as a material inducement to their employment.

16.03.2026

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations related to MYQORZO™ (aficamten) at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place March 28–30, 2026 in New Orleans, LA.

11.03.2026

Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

09.03.2026

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

15,000 shares were sold for a transaction value of approximately $928,950 at a weighted average price of around $61.93 per share on Feb. 5, 2026. The sale accounted for 22.9% of Andrew Callos' direct holdings, reducing his position from 65,440 to 50,440 shares.

02.03.2026

Cytokinetics to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.

25.02.2026

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans

CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.

Видео

28.10.2025

Positive

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
CYTK	Raymond James	Market Perform	undefined >> undefined	July 30th 2025

Пресс-релизы

18.03.2026

Cytokinetics, Incorporated (CYTK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cytokinetics, Incorporated (CYTK)

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

Cytokinetics to Participate in March Investor Conferences

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans

Видео

Повышения / Понижения рейтинга

Пресс-релизы

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy